The verifiable place to buy research peptides · Free shipping over $150
0

Research Reference · Growth-Hormone Axis

CJC-1295

A long-acting growth-hormone-releasing hormone (GHRH) analogue studied for sustained growth-hormone and IGF-1 release, often discussed with Ipamorelin.

Last reviewed September 2026 5 peer-reviewed sources 3-minute read

At a glance

CJC-1295 is a lab-made analogue of growth-hormone-releasing hormone built to last far longer than the natural hormone. In its best-known form (“with DAC”) it attaches to albumin in the blood; in healthy adults its half-life was about six to eight days. Research focuses on growth hormone and IGF-1 levels. Evidence comes from animal studies and early human studies.

TypeGHRH analogue (based on GRF 1-29)
Studied forSustained GH & IGF-1 release
Evidence stageAnimal + early human studies
Human dataStudies in healthy adults

What it’s studied for

Long-acting GH release

Sustained, dose-dependent rises in growth hormone and IGF-1 in healthy adults. 2

Human

Natural GH pulses

Growth hormone was still released in pulses during continuous stimulation. 3

Human

Growth in GHRH-deficient mice

Once-daily treatment normalized growth and body composition in knockout mice. 4

Animal

Protein biomarkers

Serum protein changes that may mark growth-hormone and IGF-1 action. 5

Human

Not currently stocked

This page is a research reference. Every product we do carry is third-party tested with a batch-matched COA.

Browse research peptides

How it works

CJC-1295 is based on the first 29 amino acids of human GHRH — the part that carries its activity — with changes that protect it from breakdown and a “drug affinity complex” (DAC) that lets it bind to albumin in the blood. In rats this produced a stable, active GHRH analogue with an extended plasma half-life. 1

In healthy adults, CJC-1295 produced sustained, dose-dependent increases in growth hormone and IGF-1, with a half-life of 5.8–8.1 days; after repeated administration IGF-1 stayed above baseline for up to 28 days. 2 Growth hormone continued to be released in pulses rather than continuously. 3

Suppliers also use the name for a version without DAC, and public database records for the two forms are inconsistent, so check which form a certificate of analysis describes.

Related research

IpamorelinOften discussed together TesamorelinFull-length GHRH analogue

Frequently asked questions

What is DAC?
Drug affinity complex — a chemical attachment that lets CJC-1295 bind albumin in the blood, greatly extending its half-life.
How long does CJC-1295 last?
In healthy adults the half-life of CJC-1295 (with DAC) was 5.8–8.1 days.
How is CJC-1295 different from Ipamorelin?
CJC-1295 acts on the GHRH receptor; Ipamorelin acts on the ghrelin (growth-hormone secretagogue) receptor. The two are often discussed together.
Has CJC-1295 been studied in humans?
Yes, in early studies in healthy adults measuring growth hormone and IGF-1. It is not an approved drug.
Do you sell CJC-1295?
Not currently. This page is a research reference.

Identifiers

Name CJC-1295
Class GHRH analogue based on hGRF(1-29)
Form in the key human studies With DAC (albumin-binding)
PubChem “CJC-1295” record CID 91971820 · CAS 446262-90-4
Status Investigational — not an approved drug

Checked against PubChem. PubChem’s records for the DAC and non-DAC forms are inconsistent, so no single molecular formula is listed here.

Research timeline

  1. 2005CJC-1295 identified as a stable, long-lasting GRF analogue that binds albumin. 1
  2. 2006Studies in healthy adults show prolonged GH and IGF-1 release 2 with pulses preserved 3; growth normalized in GHRH-knockout mice. 4
  3. 2009Serum protein profile changes linked to GH/IGF-1 activation. 5

Key studies

StudyModelWhat it found
Jetté 2005 1 Rat Bound serum albumin and stayed active with an extended plasma half-life.
Teichman 2006 2 Human · healthy adults Sustained, dose-dependent GH and IGF-1 increases; half-life 5.8–8.1 days.
Ionescu 2006 3 Human Raised trough and mean GH and IGF-1 while preserving GH pulsatility.
Alba 2006 4 Mouse Once-daily treatment maintained normal growth and body composition in GHRH-knockout mice.
Sackmann-Sala 2009 5 Human Serum protein changes proposed as biomarkers of GH/IGF-1 action.

Sources

  1. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Jetté L, et al. Endocrinology, 2005.
  2. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Teichman SL, et al. J Clin Endocrinol Metab, 2006. Human
  3. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Ionescu M, Frohman LA. J Clin Endocrinol Metab, 2006. Human
  4. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Alba M, et al. Am J Physiol Endocrinol Metab, 2006.
  5. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Sackmann-Sala L, et al. Growth Horm IGF Res, 2009. Free full textHuman
For Research Use Only. This page summarizes published scientific research for educational purposes. It is not medical advice and does not promote, recommend, or describe any human or animal use. Products referenced are sold strictly for laboratory research and are not for human consumption.

Last reviewed September 2026 by Midwest Compounds. Every source above was checked against its original publication.